企業概要
Galapagos NV is a biotechnology enterprise dedicated to the development of novel medicines primarily within the fields of oncology and immunology, with a strategic focus on markets in the United States and Europe. The company operates within the broader healthcare sector, specifically specializing in the biotechnology industry, which implies a reliance on high R&D investment and rigorous clinical trial protocols to bring proprietary therapies to market. According to the latest available data, the company holds a market capitalization of $1.92 billion and reported annual revenue of $1.11 billion over the trailing twelve months, while specific employee count data is not disclosed. The market capitalization of $1.92 billion indicates a significant scale within the biotech landscape, suggesting that the company has successfully commercialized or partnered on assets substantial enough to generate over a billion dollars in revenue, positioning it as a major player rather than a micro-cap entity.
財務健全性
The company reported revenue of $1.11 billion, net income of $319.49 million, and EBITDA of $568.17 million for the trailing twelve months, highlighting a robust operational performance. The substantial gap between the $1.11 billion revenue and the $319.49 million net income reveals a highly efficient cost structure where operating expenses are managed effectively, allowing the company to retain a significant portion of its top-line growth as profit. Free cash flow stands at $344.64 million, which provides the company with considerable financial flexibility to fund future research and development initiatives or pursue strategic acquisitions without needing immediate external capital injection. The gross margin is 56.0%, indicating that the company retains more than half of its revenue after direct costs, while the operating margin of 88.0% demonstrates exceptional control over overhead and administrative expenses. The profit margin of 28.8% further confirms that the business model is highly scalable and profitable relative to total sales. On the balance sheet, the company holds $3.00 billion in cash against a minimal debt load of $6.92 million, resulting in a conservative financial posture. This disparity is quantified by a debt-to-equity ratio of 0.21, suggesting the company is not leveraged and possesses a strong equity cushion. Additionally, the current ratio is an exceptionally high 20.14, indicating that the company's short-term liquid assets vastly exceed its short-term liabilities, ensuring ample liquidity for operational needs. Return on Equity is 10.4% and Return on Assets is 8.9%, metrics that reveal management is effectively utilizing shareholder capital and the company's asset base to generate returns that exceed the cost of capital in a low-debt environment.
バリュエーション評価
The trailing twelve-month P/E ratio is 5.04, while the forward P/E is -18.18, implying that the market is pricing in a significant decline in earnings or a specific accounting adjustment for the upcoming period that causes the forward metric to turn negative. The price-to-book ratio is 0.50, indicating that the market values the company at only half of its book value, which may suggest the market is not assigning a premium to its intangible assets or is discounting the stock due to the negative forward earnings multiple. The price-to-sales ratio is 1.72, and the EV/EBITDA is -1.95, suggesting that traditional valuation multiples are distorted by the negative forward earnings and that investors are valuing the company based on sales generation and cash flow potential rather than current profitability. The 52-week high is $37.78 and the 52-week low is $23.23; without a specific current share price provided in the facts, the precise trading position relative to this range cannot be calculated, but the wide spread indicates significant price volatility over the last year. The beta value is 0.15, which means the stock's price volatility is extremely low relative to the broader market, moving in a counter-cyclical or defensive manner compared to the overall index.
Growth & Income
Revenue growth year-over-year is an extraordinary 1093.2%, while earnings growth year-over-year is 3036.0%, indicating that earnings are expanding at a rate far exceeding the growth in revenue. This divergence implies that the company is benefiting from significant economies of scale, margin expansion, or the recognition of large partnership milestones that disproportionately boost the bottom line compared to the top line. As the company does not pay dividends, indicated by a dividend yield of N/A and a payout ratio of 0.0%, it retains all earnings to reinvest into the growth of its oncology and immunology pipeline rather than distributing cash to shareholders. The overall growth and income profile is characterized by hyper-growth in profitability and revenue, coupled with a zero-dividend policy that prioritizes capital allocation toward research, development, and commercial expansion over income generation for investors.